Denali Advisors Lifted Its Aflac Com (AFL) Position; 683 Capital Management Has Decreased By $3.83 Million Its Dicerna Pharmaceuticals (DRNA) Position

August 10, 2018 - By Glen Chin

Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) Logo

Denali Advisors Llc increased Aflac Inc Com (AFL) stake by 97.86% reported in 2018Q1 SEC filing. Denali Advisors Llc acquired 165,005 shares as Aflac Inc Com (AFL)’s stock declined 0.09%. The Denali Advisors Llc holds 333,610 shares with $14.60 million value, up from 168,605 last quarter. Aflac Inc Com now has $35.90B valuation. The stock decreased 0.23% or $0.11 during the last trading session, reaching $46.76. About 2.06M shares traded. Aflac Incorporated (NYSE:AFL) has risen 21.38% since August 10, 2017 and is uptrending. It has outperformed by 8.81% the S&P500. Some Historical AFL News: 08/03/2018 – The Klein Law Firm Reminds Investors of a Class Action on Behalf of Aflac Incorporated Shareholders and a Lead Plaintiff Deadli; 02/04/2018 – Moody’s Assigns First-time Aa3 Ifsr To Aflac Japan; Outlook Stable; 25/04/2018 – AFLAC REPORTS 1Q RESULTS, AFFIRMS 2018 OUTLOOK, DECLARES 2Q; 25/04/2018 – Aflac Delivers EPS Beat — Earnings Review; 29/05/2018 – Aflac Closes Below 50-Day Moving Average: Technicals; 25/04/2018 – Aflac 1Q Net $717M; 25/04/2018 – Aflac 1Q EPS 91c; 25/04/2018 – AFLAC 1Q ADJ. EPS EX-YEN IMPACT $1.02; 04/04/2018 – Aflac Recognized for Social Responsibility; 31/05/2018 – MEDIA-SEC is said to review allegations that Aflac misled investors – Bloomberg

683 Capital Management Llc decreased Dicerna Pharmaceuticals Inc (DRNA) stake by 77.27% reported in 2018Q1 SEC filing. 683 Capital Management Llc sold 425,000 shares as Dicerna Pharmaceuticals Inc (DRNA)’s stock rose 0.36%. The 683 Capital Management Llc holds 125,000 shares with $1.20M value, down from 550,000 last quarter. Dicerna Pharmaceuticals Inc now has $768.03 million valuation. The stock increased 1.54% or $0.22 during the last trading session, reaching $14.54. About 368,303 shares traded. Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) has risen 317.27% since August 10, 2017 and is uptrending. It has outperformed by 304.70% the S&P500. Some Historical DRNA News: 09/04/2018 – Dicerna Presenting at Conference Tomorrow; 30/05/2018 – Dicerna Doses First Primary Hyperoxaluria Patient with DCR-PHXC in Group B Portion of PHYOX Phase 1 Clinical Trial; 14/05/2018 – DICERNA PHARMACEUTICALS INC – QTRLY SHR LOSS $0.30; 17/05/2018 – Dicerna Pharmaceuticals, Inc; 08/03/2018 – DICERNA PHARMACEUTICALS INC – QTRLY SHR LOSS $0.90; 08/03/2018 – DICERNA SEES SUFFICIENT CASH TO FUND DEVELOPMENT THRU 2019; 14/05/2018 – Dicerna Pharmaceuticals 1Q Loss/Shr 30c; 14/05/2018 – Dicerna Pharmaceuticals Believes It Has Sufficient Cash Through 2019, Assuming No New Fundin; 20/04/2018 – Alnylam Reaches Settlement Agreement With Dicerna Pharmaceuticals; 20/04/2018 – DICERNA PHARMACEUTICALS INC – ALNYLAM WILL DISMISS ALL CLAIMS OF “TRADE SECRET MISAPPROPRIATION” & OTHER RELATED CLAIMS BROUGHT IN COURT AGAINST CO

683 Capital Management Llc increased Peabody Energy Corp New stake by 217,566 shares to 417,566 valued at $15.24 million in 2018Q1. It also upped Nii Holdings Inc stake by 1.37 million shares and now owns 14.05M shares. Inspired Entmt Inc was raised too.

Since March 19, 2018, it had 0 insider buys, and 4 insider sales for $425,035 activity. Weissman James B had sold 1,035 shares worth $13,455. 9,669 shares were sold by Brown Bob D, worth $145,035 on Wednesday, May 9.

Investors sentiment decreased to 2.44 in 2018 Q1. Its down 0.56, from 3 in 2017Q4. It turned negative, as 3 investors sold DRNA shares while 13 reduced holdings. 24 funds opened positions while 15 raised stakes. 30.68 million shares or 5.45% more from 29.10 million shares in 2017Q4 were reported. Northern Tru Corp has invested 0% in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA). Virtu Ltd holds 0.01% or 14,416 shares in its portfolio. 788,604 are held by Goldman Sachs Group. Bogle Limited Partnership De reported 0.01% in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA). Millennium Ltd Liability accumulated 407,530 shares or 0.01% of the stock. Renaissance Techs Ltd accumulated 289,400 shares or 0% of the stock. Emerald Advisers Pa holds 0.01% or 28,704 shares in its portfolio. Element Capital Mgmt invested in 82,957 shares. Bnp Paribas Arbitrage Sa reported 32 shares or 0% of all its holdings. Jane Street Gru Lc owns 0% invested in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) for 14,262 shares. Manchester Mgmt Limited Liability invested in 0.03% or 18,857 shares. Bancorporation Of America De stated it has 0% of its portfolio in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA). Manufacturers Life Insurance The reported 1,825 shares. Tower Ltd Liability Corp (Trc) has 1,536 shares. Jpmorgan Chase &, a New York-based fund reported 120,948 shares.

More important recent Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) news were published by: Benzinga.com which released: “Earnings Outlook For Dicerna Pharmaceuticals” on August 08, 2018, also Seekingalpha.com published article titled: “Dicerna Pharmaceuticals, Inc. (DRNA) CEO Douglas Fambrough on Q2 2018 Results – Earnings Call Transcript”, Nasdaq.com published: “Report: Developing Opportunities within Clearwater Paper, Intercept Pharmaceuticals, Community Trust, Community …” on July 25, 2018. More interesting news about Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) was released by: Businesswire.com and their article: “Dicerna to Report Second Quarter 2018 Financial Results and Host Conference Call on August 8, 2018” with publication date: July 11, 2018.

Among 6 analysts covering Dicerna Pharmaceuticals (NASDAQ:DRNA), 2 have Buy rating, 0 Sell and 4 Hold. Therefore 33% are positive. Dicerna Pharmaceuticals had 7 analyst reports since March 9, 2018 according to SRatingsIntel. The rating was maintained by Stifel Nicolaus with “Buy” on Friday, March 9. The stock of Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) earned “Hold” rating by Chardan Capital Markets on Friday, March 9. On Thursday, August 9 the stock rating was maintained by Stifel Nicolaus with “Buy”. The stock of Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) earned “Hold” rating by FBR Capital on Tuesday, March 27. H.C. Wainwright downgraded Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) on Friday, March 23 to “Neutral” rating. The stock of Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) has “Buy” rating given on Wednesday, April 11 by Cowen & Co.

Among 9 analysts covering Aflac (NYSE:AFL), 3 have Buy rating, 0 Sell and 6 Hold. Therefore 33% are positive. Aflac had 10 analyst reports since March 2, 2018 according to SRatingsIntel. The firm has “Hold” rating by Keefe Bruyette & Woods given on Tuesday, March 20. The stock has “Neutral” rating by Bank of America on Monday, March 26. The stock of Aflac Incorporated (NYSE:AFL) earned “Neutral” rating by FBR Capital on Tuesday, August 7. On Wednesday, March 21 the stock rating was maintained by Barclays Capital with “Hold”. As per Thursday, April 5, the company rating was maintained by Sandler O’Neill. The stock has “Buy” rating by Sandler O’Neill on Wednesday, August 1. JP Morgan maintained the stock with “Overweight” rating in Tuesday, March 27 report.

Denali Advisors Llc decreased Oneok Inc. (NYSE:OKE) stake by 9,400 shares to 5,800 valued at $330,000 in 2018Q1. It also reduced Lyondellbasell Industries Cl A (NYSE:LYB) stake by 11,100 shares and now owns 124,851 shares. Garmin Ltd (NASDAQ:GRMN) was reduced too.

More recent Aflac Incorporated (NYSE:AFL) news were published by: Nasdaq.com which released: “3 Important Takeaways From Aflac’s 2nd Quarter” on August 09, 2018. Also Seekingalpha.com published the news titled: “Aflac’s Q2 2018: A SWAN Stock” on July 28, 2018. Seekingalpha.com‘s news article titled: “Aflac’s (AFL) CEO Daniel Amos on Q2 2018 Results – Earnings Call Transcript” with publication date: July 27, 2018 was also an interesting one.

Investors sentiment increased to 7.76 in 2018 Q1. Its up 6.70, from 1.06 in 2017Q4. It increased, as 56 investors sold AFL shares while 35 reduced holdings. 82 funds opened positions while 624 raised stakes. 1.00 billion shares or 291.45% more from 256.45 million shares in 2017Q4 were reported. Delta Asset Mgmt Limited Liability Company Tn owns 1,185 shares for 0.01% of their portfolio. Connecticut-based Verition Fund Ltd has invested 0.03% in Aflac Incorporated (NYSE:AFL). Tradition Capital Management Ltd Com accumulated 10,850 shares. First Manhattan Company invested in 0% or 1,714 shares. Mirae Asset Glob Invs holds 0.05% in Aflac Incorporated (NYSE:AFL) or 91,572 shares. Legacy Capital has invested 0.34% of its portfolio in Aflac Incorporated (NYSE:AFL). D Scott Neal Inc invested 0% of its portfolio in Aflac Incorporated (NYSE:AFL). Sather Group Inc owns 0.1% invested in Aflac Incorporated (NYSE:AFL) for 10,016 shares. State Of New Jersey Common Pension Fund D holds 0.11% or 680,000 shares. New Mexico Educational Retirement Board owns 74,906 shares. Liberty Capital Mngmt Inc holds 2.26% of its portfolio in Aflac Incorporated (NYSE:AFL) for 85,239 shares. Boston Private Wealth Limited Liability Co reported 50,328 shares. 134,348 were accumulated by Bb&T. Leavell Investment Mngmt Inc holds 0.63% or 124,087 shares. Employees Retirement Sys Of Texas holds 0.04% or 62,000 shares.

Aflac Incorporated (NYSE:AFL) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts